Cargando…

Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis

Background: Hepatocellular carcinoma (HCC) is a serious complication of cirrhosis. Currently, non-selective beta-blockers (NSBBs) are commonly used to treat portal hypertension in patients with cirrhosis. The latest research shows that NSBBs can induce apoptosis and S-phase arrest in liver cancer ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Xinyi, Zhao, Zimo, Jiang, Xi, Sun, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394622/ https://www.ncbi.nlm.nih.gov/pubmed/37538177 http://dx.doi.org/10.3389/fphar.2023.1216059

Ejemplares similares

Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation
por: Cheng, He-Yun, et al.
Publicado: (2022)

Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis
por: Zhao, Zimo, et al.
Publicado: (2023)

Beta-blockers in liver cirrhosis
por: Giannelli, Valerio, et al.
Publicado: (2014)

Long-Term Effect of Non-Selective Beta-Blockers in Patients With Rheumatoid Arthritis After Myocardial Infarction—A Nationwide Cohort Study
por: Liu, Sheng-Fu, et al.
Publicado: (2021)

Systematic Review and Meta-analysis: Association of Aspirin With Incidence of Hepatocellular Carcinoma
por: Zhou, Xueliang, et al.
Publicado: (2022)

Beta-blockers in cardiac arrhythmias–Clinical pharmacologist’s point of view
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

Treatment with non‐selective beta‐blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis
por: Gimenez, Paula, et al.
Publicado: (2018)

Beta-blockers in cirrhosis: Evidence-based indications and limitations
por: Rodrigues, Susana G., et al.
Publicado: (2019)

Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023)

New Insights into Cardiac and Brain Sodium Channels Modulation by Beta Blockers
por: Chahine, Mohamed
Publicado: (2011)

The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome
por: Kummer, Marvin, et al.
Publicado: (2020)

Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation
por: Ngwa, Taiwo, et al.
Publicado: (2020)

Non-Selective Beta-Blockers and Risk of Sepsis in Patients with Cirrhosis and Ascites: Results from a Large Observational Study
por: Jensen, Morten Daniel, et al.
Publicado: (2023)

Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different β1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study
por: Sessa, Maurizio, et al.
Publicado: (2018)

Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?
por: Nabilou, Puria, et al.
Publicado: (2022)

Characteristic interactivity of landiolol, an ultra-short-acting highly selective β(1)-blocker, with biomimetic membranes: Comparisons with β(1)-selective esmolol and non-selective propranolol and alprenolol
por: Tsuchiya, Hironori, et al.
Publicado: (2013)

Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC)
por: Le Bozec, Antoine, et al.
Publicado: (2023)

Using administrative healthcare data to evaluate drug repurposing opportunities for cancer: the possibility of using beta-blockers to treat breast cancer
por: Tan, George S. Q., et al.
Publicado: (2023)

Use of Non-Selective Beta-Blocker for Refractory Stomal Variceal Hemorrhage
por: Mu, Xin, et al.
Publicado: (2021)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

Nonselective beta-blocker use is associated with increased hepatic encephalopathy-related readmissions in cirrhosis
por: Fallahzadeh, Mohammad Amin, et al.
Publicado: (2022)

Beta-blockers in post-acute myocardial infarction patients: Drug prescription patterns from 2018 to Italy’s first wave of the COVID-19 pandemic
por: Olmastroni, Elena, et al.
Publicado: (2022)

Discovery and Development of Calcium Channel Blockers
por: Godfraind, Théophile
Publicado: (2017)

Incidence, Mortality, and Predictive Factors of Hepatocellular Carcinoma in Primary Biliary Cirrhosis
por: Hosonuma, Kenichi, et al.
Publicado: (2013)

Extract of Marsdenia tenacissima (Roxb.) Moon [Apocynaceae] Suppresses Hepatocellular Carcinoma by Inhibiting Angiogenesis
por: Pan, Yating, et al.
Publicado: (2022)

Is the use of non-selective beta-blockers necessary in cirrhotic patients with small varices?
por: Qi, Xingshun, et al.
Publicado: (2014)

Adherence to Non-Selective Beta Blockers for Prevention of Variceal Bleeding in Cirrhotic Patients
por: An, Yang, et al.
Publicado: (2021)

Role of ferroptosis and its non-coding RNA regulation in hepatocellular carcinoma
por: Yang, Lei, et al.
Publicado: (2023)

Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
por: Tovo, Cristiane Valle, et al.
Publicado: (2023)

Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
por: Tian, Xinchen, et al.
Publicado: (2022)

The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis
por: Ma, Xiao, et al.
Publicado: (2016)

Spatial metabolomics on liver cirrhosis to hepatocellular carcinoma progression
por: He, Michelle Junyi, et al.
Publicado: (2022)

Effects of Glycolysis-Related Genes on Prognosis and the Tumor Microenvironment of Hepatocellular Carcinoma
por: Zheng, Ju-Yan, et al.
Publicado: (2022)

Meta-analysis of the benefit of beta-blockers for the reduction of isolated atrial fibrillation incidence after cardiac surgery
por: Masuda, Yoshio, et al.
Publicado: (2020)

Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance
por: Ganne-Carrié, Nathalie, et al.
Publicado: (2021)

Daily Aspirin Reduced the Incidence of Hepatocellular Carcinoma and Overall Mortality in Patients with Cirrhosis
por: Lee, Chern-Horng, et al.
Publicado: (2023)

Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma
por: Lai, Shih-Wei, et al.
Publicado: (2017)

Association Between Prior Calcium Channel Blocker Use and Mortality in Septic Patients: A Meta-Analysis of Cohort Studies
por: Ding, Xianfei, et al.
Publicado: (2021)

Capsule Networks Showed Excellent Performance in the Classification of hERG Blockers/Nonblockers
por: Wang, Yiwei, et al.
Publicado: (2020)

Histamine2-Receptor Antagonists, Proton Pump Inhibitors, or Potassium-Competitive Acid Blockers Preventing Delayed Bleeding After Endoscopic Submucosal Dissection: A Meta-Analysis
por: Jiang, Xin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oo0maaod9615la87j214dq9hbk